Pharmaceuticals
LIST1043Related Stocks
News
Weight-Loss Drug Giant Eli Lilly Bets Big Again. Spending $7.8 Billion to Acquire Centessa, Is Now a Good Time to Buy Eli Lilly?
TradingKey - On March 31, Eastern Time, Eli Lilly officially announced its acquisition of U.S.-listed Centessa Pharmaceuticals for a total consideration of $7.8 billion, with the transaction expected to close in the third quarter of 2026. Following the news, Eli Lilly shares rose approximately 3% on Tuesday, while Centessa shares surged 45%.
Today’s Market Recap: Markets Edge Up Amid Iran Conflict and Fed Rate Scrutiny
U.S. indices edged higher as investors weighed optimistic tech developments from Nvidia, Amazon, and Micron against a volatile geopolitical backdrop.
Rhythm Pharma's Drug Fails Key Genetic Obesity Trial, Shares Fall
March 16 (Reuters) - Rhythm Pharmaceuticals RYTM.O said on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial.
What Are Defensive Stocks? Best Defensive Stocks to Buy in 2026
TradingKey - Defensives run on resilience: predictable demand, strong cash flow, conservative balance sheets, and tame volatility. You can’t just look at a sector name to find them. It requires a systematic examination of cash generation, leverage, dividend sustainability, beta, competitive moats, a
Hims & Hers Soars 64% in Three Days as Novo Nordisk Deal Opens Door to GLP-1 Market
TradingKey - Shares of Hims & Hers Health (HIMS.US) surged nearly 64% cumulatively over the first three trading days of this week, with an intraday rally of over 10% on Wednesday.
Novartis AG Stock (NVS) Moved Down by 3.16% on Mar 11: Drivers Behind the Movement
• Novartis stock declined due to trading ex-dividend for $4.773 per share. • Q4 2025 earnings beat expectations, but revenue missed analyst targets. • 2026 operating profit forecast projects a low single-digit percentage decline.
